Last Friday, the issue fell from $23.44 to $18.50 over concerns in its 10-Q relating to other scrutiny from the FDA concerning another drug in the pipeline.
After a lower open, it rallied a dollar to $12.75 before resuming its decline. It has continued to make news for the session with the current one standing at $9.75. That low comes in just above its September 2014 low of $9.61.
Today's price action is taking place on much heavier than average volume. With just under six hours remaining, 4.2 million shares have already traded compared to its 20-day average of 1.2 million.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.